113 related articles for article (PubMed ID: 899943)
1. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.
Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH
Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943
[No Abstract] [Full Text] [Related]
2. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
Peacock M; Davison AM; Walker GS
Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
[No Abstract] [Full Text] [Related]
3. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
4. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
Peacock M; Aaron JE; Walker GS; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
[No Abstract] [Full Text] [Related]
5. Controlled therapeutic trial of 1alpha-hydroxycholecalciferol in chronic renal failure.
Tougaard L; Sörensen E; Bröchner-Mortensen J; Christensen MS; Rödbro P; Sörensen AW
Calcif Tissue Res; 1977 May; 22 Suppl():101-4. PubMed ID: 334342
[No Abstract] [Full Text] [Related]
6. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
[TBL] [Abstract][Full Text] [Related]
7. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
8. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
[No Abstract] [Full Text] [Related]
9. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.
Tougaard L; Sorensen E; Brochner-Mortensen J; Christensen MS; Rodbro P; Sorensen AW
Lancet; 1976 May; 1(7968):1044-7. PubMed ID: 57451
[TBL] [Abstract][Full Text] [Related]
10. Calcium and parathyroid disorders in children. Chronic renal failure and treatment with calcitriol.
Chan JC; DeLuca HR
JAMA; 1979 Mar; 241(12):1242-4. PubMed ID: 762789
[TBL] [Abstract][Full Text] [Related]
11. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
Postlethwaite RJ; Houston IB
Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
[No Abstract] [Full Text] [Related]
12. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
Reutter FW; Sieber R; Olah AJ; Dambacher MA
Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
[TBL] [Abstract][Full Text] [Related]
13. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
[No Abstract] [Full Text] [Related]
14. Calcifediol in chronic renal insufficiency. Skeletal response.
Teitelbaum SL; Bone JM; Stein PM; Gilden JJ; Bates M; Boisseau VC; Avioli LV
JAMA; 1976 Jan; 235(2):164-7. PubMed ID: 946022
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.
Brickman AS; Coburn JW; Norman AW; Massry SG
Am J Med; 1974 Jul; 57(1):28-33. PubMed ID: 4600292
[No Abstract] [Full Text] [Related]
16. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
[No Abstract] [Full Text] [Related]
17. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
[TBL] [Abstract][Full Text] [Related]
18. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia.
Peacock M; Aaron JE; Heyburn PJ; Nordin BE
Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935
[No Abstract] [Full Text] [Related]
19. Minor influence of parathyroid hormone on fractional tubular reabsorption of phosphate in chronic renal failure.
Christensen MS; Brochner-Mortensen J; Tougaard L; Sorensen E; Rodbro P
Adv Exp Med Biol; 1977; 81():131-9. PubMed ID: 899922
[TBL] [Abstract][Full Text] [Related]
20. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
